521 completed. 521 Phase 3, 59 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 521 | Completed 521 |
| Phase 2 | 59 | Completed 59 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy LCZ, LCZ/AML 200 mg/2.5 mg, LCZ/AML 200 mg/5 mg - Hypertension | Phase 3 | Completed | Novartis Pharmaceuticals | 718 | 2024-04-08 | 2026-01-13 |
| Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care - Mild Cognitive Impairment, Dementia, Mild | Phase 3 | Completed | Alzheimer's Prevention and Reversal Project, Inc. | 73 | 2023-07-31 | 2026-02-18 |
| Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities Mesh - spatial repellent impregnated with transfluthrin (2500mg), Information and Education Campaigns (IEC), test and treat malaria cases - Malaria, Childhood ALL | Phase 3 | Completed | The Mentor Initiative | 2400 | 2023-06-05 | 2024-04-23 |
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma Isatuximab, Lenalidomide, Bortezomib - Multiple Myeloma | Phase 3 | Completed | University of Heidelberg Medical Center | 514 | 2023-04-14 | 2026-02-18 |
| ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE) Recombinant Human Prourokinase for Injection (rhPro-UK), standard medical treatment - Ischemic Stroke, Mild | Phase 3 | Completed | Beijing Tiantan Hospital | 1446 | 2022-11-15 | 2024-09-05 |
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo - Pulmonary Sarcoidosis | Phase 3 | Completed | aTyr Pharma, Inc. | 268 | 2022-09-15 | 2026-06-04 |
| Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Mepolizumab, cyclophosphamide/azathioprine, Placebo - Eosinophilic Granulomatosis With Polyangiitis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 102 | 2022-05-30 | 2026-10-01 |
| Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19 Tanreqing capsule, Tanreqing capsule simulator - Novel Coronavirus Pneumonia | Phase 3 | Completed | Jiangsu Famous Medical Technology Co., Ltd. | 480 | 2022-03-28 | 2022-12-06 |
| EXHIT ENTRE Comparative Effectiveness Trial Extended Release Buprenorphine, Treatment as Usual - Substance Use Disorder, Opioid Use Disorder, Moderate | Phase 2 / Phase 3 | Completed | Gavin Bart | 344 | 2021-08-09 | 2025-12-09 |
| Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) Polatuzumab Vedotin, Mabthera, Ifosfamide - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Completed | GWT-TUD GmbH | 306 | 2021-04-30 | 2026-06-10 |
| Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) Panzyga, Placebo - Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | Phase 3 | Completed | Octapharma | 247 | 2020-10-05 | 2026-11-02 |
| Moxidectin for LF, Cote d'Ivoire (DOLF) Ivermectin, Diethylcarbamazine, Albendazole - Lymphatic Filariasis | Phase 3 | Completed | Washington University School of Medicine | 164 | 2020-08-20 | 2026-01-29 |
| Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes HCL, verapamil 120mg tablet, non-HCL - Type1 Diabetes | Phase 3 | Completed | Jaeb Center for Health Research | 113 | 2020-07-09 | 2024-11-27 |
| Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma - Pneumococcal Infections, Lymphoma, Large B-Cell, Diffuse | Phase 3 | Completed | University Hospital, Tours | 26 | 2020-07-03 | 2026-02-12 |
| A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Obinutuzumab, Venetoclax, Fludarabine - Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Completed | Hoffmann-La Roche | 166 | 2020-05-28 | 2026-03-03 |
| Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone), Tucidinostat, Placebo - Diffuse Large B-cell Lymphoma | Phase 3 | Completed | Chipscreen Biosciences, Ltd. | 423 | 2020-05-21 | 2026-04-08 |
| A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Rituximab, Gemcitabine - Diffuse Large B-Cell Lymphoma | Phase 3 | Completed | Hoffmann-La Roche | 270 | 2020-02-07 | 2025-12-22 |
| Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease IVIG, Aspirin, Prednisolone - Kawasaki Disease | Phase 3 | Completed | Children's Hospital of Fudan University | 3208 | 2020-01-15 | 2026-04-16 |
| An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) IM JZP-458, IV JZP-458 - Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Completed | Jazz Pharmaceuticals | 229 | 2019-12-27 | 2023-11-18 |
| Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 3 | Completed | AstraZeneca | 552 | 2019-09-17 | 2026-09-01 |
Showing 20 of 521. Sign in to see all of them.
Lymphoma (125) · Lymphoma, Follicular (120) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (111) · Lymphoma, Non-Hodgkin (109) · Leukemia, Lymphocytic, Chronic, B-Cell (96) · Lymphoma, Large B-Cell, Diffuse (84) · Leukemia (68) · Hodgkin Disease (63) · Lymphoma, Mantle-Cell (46) · Leukemia, Myeloid, Acute (44) · Burkitt Lymphoma (43) · Multiple Myeloma (42) · Lymphoma, B-Cell, Marginal Zone (39) · Lymphoma, Large-Cell, Immunoblastic (38) · Myelodysplastic Syndromes (31)
Hemic and Lymphatic Diseases (521) · Immune System Diseases (485) · Lymphoproliferative Disorders (470) · Neoplasms by Histologic Type (454) · Immunoproliferative Disorders (453) · Neoplasms (435) · Hematologic Diseases (234) · Lymphoma (198) · Leukemia, Lymphoid (183) · Pathological Conditions, Signs and Symptoms (159) · Lymphoma, Non-Hodgkin (152) · Pathologic Processes (143) · Leukemia (136) · Disease Attributes (128)
Rituximab (122) · Cyclophosphamide (121) · Vincristine (90) · Doxorubicin (85) · Prednisone (70) · Methotrexate (51) · Cytarabine (49) · Etoposide (45) · Dexamethasone (43) · Radiotherapy (39) · Filgrastim (33) · Mercaptopurine (30) · fludarabine (26) · Bendamustine Hydrochloride (25) · Granulocyte Colony-Stimulating Factor (24)
Children's Oncology Group (28) · Hoffmann-La Roche (24) · Pfizer (11) · Novartis Pharmaceuticals (10) · Amgen (9) · Assistance Publique - Hôpitaux de Paris (9) · Celgene (9) · German CLL Study Group (9) · Fred Hutchinson Cancer Center (7) · French Innovative Leukemia Organisation (7) · Lymphoma Study Association (7) · M.D. Anderson Cancer Center (7) · National Cancer Institute (NCI) (7) · Pharmacyclics LLC. (7) · St. Jude Children's Research Hospital (7)
United States (265) · France (144) · Germany (137) · Canada (125) · United Kingdom (123) · Italy (118) · Australia (107) · Spain (104) · Belgium (93) · Poland (78) · Netherlands (64) · Austria (61) · Russia (61) · Czechia (60) · Switzerland (56)
Michael Hallek, MD (6) · Frederick Beddingfield, MD, PhD (4) · Eric Ottesen, MD (3) · Mary Horowitz, MD (3)
PMID 40135712, PMID 39121442, PMID 38620092, PMID 28751558, PMID 32816215, PMID 37505794, PMID 37890117, PMID 40266025, PMID 11873261, PMID 22610930, PMID 31196847, PMID 32228663, PMID 33131249, PMID 33288485, PMID 34515338, PMID 38446568, PMID 10656038, PMID 23065509, PMID 23233721, PMID 24797299, PMID 24916506, PMID 24970932, PMID 26149717, PMID 26373676, PMID 26590194, PMID 27282998, PMID 27695295, PMID 28396102, PMID 29255066, PMID 29284596, PMID 29880603, PMID 30010775, PMID 31050355, PMID 31188727, PMID 31612640, PMID 32374962, PMID 32499241, PMID 32632956, PMID 32735048, PMID 33242441, PMID 34865212, PMID 35014928, PMID 35377947, PMID 35787017, PMID 35829925, PMID 36617990, PMID 37341189, PMID 38502198, PMID 38662147, PMID 38796193
U10CA098543 (16), 2009 (8), 2016 (8), 2008 (7), 2014 (7), 2015 (6), 2023 (5), 2005 (4), 2017 (4), U01HL069294 (4), U10CA032102 (4), U10CA095861 (4), U10CA180886 (4), 2018 (3), 2019 (3)